Innovation

Novel Imaging Agent to Image and Quantify Beta-Cell Mass

Massachusetts General Hospital
posted on 02/26/2012

The Technology: The inventors have developed a novel imaging agent that enables the imaging and quantification of beta-cell mass in vivo. The inventors have demonstrated this agent in both in vitro cell-based assays and in vivo preclinical studies. Applications: This imaging agent allows for significantly improved evaluation of potential therapies for diabetes in preclinical and clinical research. Further, this agent could be a valuable tool for the non-invasive monitoring of diabetes (e.g. disease progression and response to treatment) in a clinical context. Advantages: - There is a large unmet clinical need to quantify beta-cell mass in vivo - currently, there is no diagnostic test to accurately detect loss of beta cell mass in vivo. - The ability to quantify beta-cell mass would enable the further study of diabetes biology, the monitoring of disease progression or response to treatment. - Potentially enables the earlier diagnosis of type 1 diabetes by distinguishing between healthy individuals and occult diabetics.


Innovation Details
 

File Number: 20780 

Other Information: *Investigator(s)*
Ralph Edmund ; Weissleder Thomas ; Keliher Reiner

*Contact*
Daniel Castro, 617-954-9325


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Beth Mollineaux at Massachusetts General Hospital for more information.

Request more info via email request more info
People

Case Manager:

Beth Mollineaux Beth Mollineaux

Innovations (0)


Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Communities
Profile
Related Tags

Find more innovations


February 11, 2009

13,134 members 17,507 innovations 176 organizations

Browse

David Kolb, CEO and chairman of the board, Emunamedica LLC.

"We found tremendous value and benefit in using the iBridge Network..."  read more...